Future of sentinel node biopsy in ovarian cancer

Nicolò Bizzarri,Camilla Nero,Stefano Di Berardino,Giovanni Scambia,Anna Fagotti
DOI: https://doi.org/10.1097/cco.0000000000001058
2024-07-19
Current Opinion in Oncology
Abstract:Ovarian cancer (OC) is the most lethal gynecological cancer with approximately 314 000 diagnoses and 207 000 deaths worldwide in 2020 [1] . In 15–20% of cases it is diagnosed at an apparent early-stage of disease and comprehensive surgical staging including systematic pelvic and para-aortic lymphadenectomy is required in epithelial histologies [2] . The concept of sentinel lymph node (SLN) has been successfully implemented in uterine and vulvar cancers with international guidelines endorsing its use as method for assessing lymph node status [3–5] . Compared to systematic lymphadenectomy, SLN offers the advantage of reducing intra- and post-operative morbidity and to increase the diagnostic accuracy thanks to the ultrastaging method, which allows the detection of low-volume metastases [6] . SLN concept in OC staging has been investigated later in time compared with vulvar and uterine cancers [7] . Its use in the surgical staging of apparent early-stage OC is supported by the fact that therapeutic role of lymphadenectomy is still matter of controversy [8▪] . Nevertheless, the staging and prognostic value of nodal status remains pivotal in indicating adjuvant therapy and maintenance treatment.
oncology
What problem does this paper attempt to address?